CureVac NV (CVAC)

Stay updated with CureVac NV (CVAC) share price analysis and insights to guide your investment strategy. Stay informed with FP Markets .

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

CureVac NV (CVAC) Profile

CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic acid (mRNA). It is working to develop prophylactic vaccines, including CV7202, a prophylactic mRNA-based vaccine candidate against COVID-19; a vaccine for lassa yellow fever; a vaccine for the respiratory syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and immunisations against Rota, malaria, and universal influenza. Additionally, the company is developing RNA-based cancer immunotherapies, comprising ofCV8102 (BI 1361849), a self-adjuvanting mRNA vaccine in Phase 1 clinical trials for non-small cell lung cancer, and also tumour-associated antigens and shared neo-antigens. Additionally, the company is developing protein-based therapeutics for Cas9 gene editing, ophthalmic and respiratory illnesses, as well as therapeutic antibodies. The headquarters of the corporation are in T14 Bingen, Germany. Full Time Employees: 455 latest stock price29.860.00 (0.00%) At close: 04:00 PM as at 1/12/2022 EST. Market cap 5,585B USD. CureVac total assets for the quarter ending September 30, 2021, were $1.588B.

CureVac NV (CVAC.xnas) News
CureVac is developing CV2CoV, a preclinical second-generation mRNA vaccine potential, against SARS-CoV-2 in partnership with GlaxoSmithKline Plc (NYSE: GSK). In Q1 2022, the business plans to initiate a Phase 1 trial evaluating CV2CoV.

Start Trading CureVac NV (CVAC) with a Market Leader Today

CureVac NV (CVAC) Trading FAQ

Shares represent units of ownership within a company. Shares are also known as stocks or equities. Dividend payments are common with some companies, a method of sharing company profits with shareholders. In addition to traditional share dealing, however, traders can access derivatives: trading instruments derived from the movement of an underlying share price.

Individual stock CFDs (contract for differences) fall under the umbrella of derivative products, an effective low-cost trading vehicle. While CFDs do not grant shareholder privileges, active CFD positions may receive a dividend if executed before the ex-dividend date.

Start Trading
in minutes

Get instant Updates in Telegram